Pharma BD Deal Intelligence
BMS taps Eisai's Alzheimer's partner BioArctic in $1.35B deal; anti-pyroglutamate amyloid approach is differentiated but field has mixed track record
Bristol Myers Squibb invests $100M in BioArctic for next-generation Alzheimer's therapies using BrainTransporter technology.
BioArctic Q1 2026 interim report: BMS solely responsible for development and commercialization of BAN1503 and BAN2803; program remains preclinical, no…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
BMS licensed BioArctic's anti-amyloid antibodies BAN1503 and BAN2803 for Alzheimer's disease development and commercialization.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / BioArctic AB (this deal) | 2024 | $1.4B | 65 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2024 deals · Bristol-Myers Squibb Company deals · Neurology deals